Eikon Therapeutics: ADIA reports 2.1% passive stake

Platinum Falcon directly owns the reported shares, while its parent, ADIA, may also be deemed their beneficial owner.

Rhea-AI Filing Summary

Eikon Therapeutics, Inc. is the issuer in an amended beneficial-ownership report showing 1,147,138 common shares, or 2.1%, attributed to Abu Dhabi Investment Authority (ADIA) and its wholly owned subsidiary, Platinum Falcon B 2018 RSC Limited. Platinum Falcon directly owns the shares, while ADIA may be deemed their beneficial owner; each reports shared voting and dispositive power over the same 1,147,138 shares and zero sole voting or dispositive power.

The 2.1% calculation is based on 54,165,030 Eikon shares outstanding as of August 3, 2026. The reporting persons identify themselves as owning 5% or less of the class.

Key Figures

Beneficially owned common shares: 1,147,138 shares Ownership of class: 2.1% Common shares outstanding: 54,165,030 shares

3 metrics

Beneficially owned common shares 1,147,138 shares Reported by each reporting person; Platinum Falcon directly owns the shares

Ownership of class 2.1% Based on shares outstanding as of August 3, 2026

Common shares outstanding 54,165,030 shares As of August 3, 2026

Key Terms

beneficial owner, shared voting power, shared dispositive power

3 terms

beneficial owner regulatory

"may be deemed to be the beneficial owner"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

shared voting power regulatory

"Shared Voting Power 1,147,138.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power regulatory

"Shared Dispositive Power 1,147,138.00"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many EIKN shares do ADIA and Platinum Falcon report?

Abu Dhabi Investment Authority and Platinum Falcon B 2018 RSC Limited each report 1,147,138 common shares, representing 2.1% of Eikon Therapeutics, Inc.'s class. Platinum Falcon directly owns the shares, while ADIA may be deemed their beneficial owner.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 11:14 AM Accepted by SEC EDGAR 10/02/2026 - 11:14 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Eikon Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

282564103

(CUSIP Number)

09/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 282564103

1

Names of Reporting Persons

Abu Dhabi Investment Authority

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED ARAB EMIRATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,147,138.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,147,138.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,147,138.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.1 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: (1) The percent calculation is based on 54,165,030 shares of Common Stock outstanding as of August 3, 2026, as disclosed in Eikon Therapeutics, Inc.'s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026, filed with the U.S. Securities and Exchange Commission (the "SEC") on August 13, 2026 (the "Form 10-Q").

SCHEDULE 13G

CUSIP Number(s): 282564103

1

Names of Reporting Persons

Platinum Falcon B 2018 RSC Limited

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED ARAB EMIRATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,147,138.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,147,138.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,147,138.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.1 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: (1) Platinum Falcon B 2018 RSC Limited ("Platinum Falcon") is the direct owner of 1,147,138 of the shares of Common Stock reported herein. Platinum Falcon is a wholly owned subsidiary of Abu Dhabi Investment Authority. Pursuant to the rules and regulations of the SEC, Abu Dhabi Investment Authority may be deemed to be the beneficial owner of the shares of Common Stock directly held by Platinum Falcon. (2) The percent calculation is based on 54,165,030 shares of Common Stock outstanding as of August 3, 2026, as disclosed in Eikon Therapeutics, Inc.'s Form 10-Q.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Eikon Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 230 Harriet Tubman Way, Millbrae CA 94030
Item 2.
(a)	Name of person filing: This Schedule 13G/A is being filed on behalf of the following: 1. Abu Dhabi Investment Authority 2. Platinum Falcon B 2018 RSC Limited
(b)	Address or principal business office or, if none, residence: The principal business address of each of the Reporting Persons is as follows: 1. 211 Corniche Street P.O. Box 3600 Abu Dhabi, United Arab Emirates 3600 2. Level 26, Al Khatem Tower Abu Dhabi Global Market Square Al Maryah Island, Abu Dhabi United Arab Emirates
(c)	Citizenship: 1. Abu Dhabi Investment Authority (ADIA) is a public institution established by the Government of the Emirate of Abu Dhabi in 1976 as an independent investment institution. 2. Platinum Falcon B 2018 RSC Limited is a restricted scope company organized under the laws of the Abu Dhabi Global Market, Abu Dhabi, United Arab Emirates.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 282564103
Item 4.	Ownership
(a)	Amount beneficially owned: See responses to Item 9 on each cover page.
(b)	Percent of class: See responses to Item 11 on each cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See responses to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See responses to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See responses to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See responses to Item 8 on each cover page.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Abu Dhabi Investment Authority

Signature:	/s/ Saif Almashghouni
Name/Title:	Saif Almashghouni / Authorized Signatory
Date:	10/02/2026

Signature:	/s/ Ahmed AlNeyadi
Name/Title:	Ahmed AlNeyadi / Authorized Signatory
Date:	10/02/2026

Platinum Falcon B 2018 RSC Limited

Signature:	/s/ Saif Almashghouni
Name/Title:	Saif Almashghouni / Authorized Signatory
Date:	10/02/2026

Signature:	/s/ Ahmed AlNeyadi
Name/Title:	Ahmed AlNeyadi / Authorized Signatory
Date:	10/02/2026